Adello’s Filgrastim Biosimilar Faces Infringement Lawsuit And Potential Regulatory Delay
Executive Summary
US FDA user fee date for privately held company’s 351(k) application referencing Amgen’s Neupogen may have passed without word of a regulatory action; Amgen sued Adello in March alleging infringement of 17 patents covering the innovator product.